5-Amino-1MQ, Research Reference

5-Amino-1MQ (5-Amino-1-methylquinolinium) is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and epigenetic regulation. It is not a peptide but a small molecule quinolinium salt, and is included in this research reference because it is commonly sourced and researched alongside peptides in metabolic and longevity research contexts.

Quick Reference

Overview

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the methylation of nicotinamide and implicated in adipose tissue metabolism, epigenetic regulation, and insulin sensitivity. It is not a peptide. It is classified as a small molecule NNMT inhibitor and is included here because it is commonly researched alongside peptides in metabolic and longevity contexts, and is available through many of the same research compound suppliers.

Most of the evidence for 5-Amino-1MQ comes from preclinical rodent studies. These have reported significant reductions in fat mass, improved insulin sensitivity, and favourable changes in lipid profiles following NNMT inhibition. Human clinical trial data is very limited as of this writing, and the extrapolation of rodent metabolic findings to humans carries well- documented uncertainty.

Mechanism of Action

NNMT catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) onto nicotinamide (a form of vitamin B3), producing 1-methylnicotinamide and S-adenosylhomocysteine as byproducts. This reaction is significant for two reasons:

• SAM consumption: SAM is the primary methyl donor for a wide range of epigenetic methylation reactions, including histone and DNA methylation. Excessive NNMT activity depletes the cellular SAM pool, reducing the methyl group availability required for normal epigenetic regulation.
• Nicotinamide fate: Nicotinamide that is methylated by NNMT is diverted away from the NAD+ biosynthesis pathway. NNMT is highly expressed in adipose tissue and is upregulated in obesity, creating a state of both reduced methyl donor availability and reduced NAD+ precursor flux in metabolically dysfunctional fat tissue.

By inhibiting NNMT, 5-Amino-1MQ is proposed to produce the following downstream effects:

• Increase intracellular NAD+ precursor availability by redirecting nicotinamide toward NAD+ synthesis rather than methylation
• Increase SAM availability for epigenetic methylation reactions
• Reduce lipid accumulation in adipocytes through altered gene expression in fat tissue
• Increase energy expenditure in adipose tissue

In rodent studies, NNMT inhibition has produced reductions in fat mass without caloric restriction, alongside improvements in insulin sensitivity and metabolic markers. The mechanism is mechanistically distinct from direct NAD+ precursors such as NMN or NR, which add substrate upstream of the NAD+ synthesis pathway rather than redirecting it.

Reported Research Effects

The following effects have been reported in preclinical research contexts. Human data is very limited; these findings should not be interpreted as confirmed effects in humans.

Fat Mass Reduction

Rodent studies using 5-Amino-1MQ and related NNMT inhibitors have reported significant reductions in fat mass without concurrent caloric restriction. The proposed mechanism is increased energy expenditure within adipose tissue, driven by altered gene expression programs downstream of NNMT inhibition, alongside reduced lipogenesis in adipocytes. These effects were observed at doses tolerated without apparent toxicity in the rodent models studied.

Muscle Preservation

Some rodent data suggests NNMT inhibition may support lean mass retention during caloric deficit. This is mechanistically plausible given NNMT’s role in energy substrate regulation, but the evidence base for this specific effect is less developed than for fat mass reduction and warrants cautious interpretation.

NAD+ Pathway Effects

By reducing nicotinamide methylation, NNMT inhibition is proposed to increase substrate availability for NAD+ synthesis. This positions 5-Amino-1MQ as having overlapping metabolic interest with NAD+ precursors, though the mechanism differs: rather than adding substrate, NNMT inhibition redirects existing nicotinamide away from the methylation pathway and toward NAD+ synthesis. The practical significance of this distinction in terms of intracellular NAD+ levels has not been conclusively established in human tissue.

Metabolic Markers

Rodent studies have reported improvements in insulin sensitivity and lipid profiles following NNMT inhibition, consistent with the expected metabolic consequences of reduced adipose tissue dysfunction and improved energy substrate handling. These findings are preclinical; no human trial data confirms equivalent effects.

Reported Protocols

The following information represents dosing ranges derived from community research accounts and rodent study dose scaling estimates. No human dose-finding trial data is available.

• Most commonly reported dose: 50 mg once daily, oral
• Higher dose reports: 100 mg daily, sometimes split into two 50 mg doses
• Cycle length: No established guidance; commonly used in 8–12 week cycles based on community reports
• Timing: Typically reported as morning dosing, though no pharmacokinetic rationale for specific timing has been established
• Common stacks: Often used alongside NAD+ precursors (NMN, NR) given the overlapping involvement in nicotinamide metabolism pathways; some community reports include combination with metabolic peptides such as MOTS-c

No clinical dose-response data for humans exists. Community-derived dose information represents anecdotal research context only.

Reported Side Effects

The side effect profile of 5-Amino-1MQ in humans is poorly characterised due to the limited human data available.

Notes on the evidence base:

• No serious adverse events have been reported in available rodent studies at research doses
• Community reports generally describe 5-Amino-1MQ as well tolerated at 50–100 mg daily
• Long-term safety in humans is unknown; no long-term human safety data has been published
• The absence of reported serious effects in rodent studies and community accounts does not constitute a human safety characterisation

Evidence Limitations

The evidence base for 5-Amino-1MQ in humans is very limited. This warrants direct acknowledgement:

The metabolic effects observed in rodent models are mechanistically compelling and internally consistent: NNMT inhibition reduces fat mass, improves insulin sensitivity, and alters epigenetic methylation patterns in a direction consistent with improved metabolic health. However, rodent-to-human translation in metabolic research is historically unreliable. Rodent adipose tissue physiology, metabolic rate, and NNMT expression patterns differ from humans in ways that may affect how well these findings translate.

No completed human clinical trials for 5-Amino-1MQ have been published as of the knowledge cutoff. No human dose-response data, human pharmacokinetic data, or controlled human efficacy data is available. The community research accounts that form the primary anecdotal evidence base for human use are subject to all the limitations of uncontrolled self-experimentation.

Researchers considering 5-Amino-1MQ should weigh this evidence gap carefully against the mechanistic rationale. A plausible mechanism supported by rodent data is a starting point for investigation, not a confirmation of human efficacy or safety.

Storage and Handling

5-Amino-1MQ is typically supplied as a dry powder or capsule for oral use. No reconstitution is required.

• Dry powder or capsules: Store at room temperature, away from light and moisture, in a sealed container
• Refrigeration: Not required; room temperature storage is standard
• Shelf life: Typically reported as 2 years from manufacture when stored correctly
• No injection preparation required: Oral administration only in available research use

Frequently Asked Questions

What does 5-Amino-1MQ do? 5-Amino-1MQ inhibits NNMT, an enzyme that methylates nicotinamide and consumes SAM in the process. By blocking this reaction, the compound is proposed to increase NAD+ precursor availability, improve methyl group availability for epigenetic reactions, and reduce lipogenic activity in adipose tissue. Rodent studies have reported fat mass reduction and metabolic improvement. Human evidence is very limited.

Is 5-Amino-1MQ a peptide? No. 5-Amino-1MQ is a small molecule quinolinium salt, not a peptide. It is listed on this site because it is commonly researched and sourced alongside peptides in metabolic contexts and is available through many of the same research compound suppliers.

What is NNMT and why does inhibiting it matter? NNMT (nicotinamide N-methyltransferase) catalyses the methylation of nicotinamide using SAM as the methyl donor. It is highly expressed in adipose tissue and upregulated in obesity. Excessive NNMT activity depletes the SAM pool needed for epigenetic methylation and diverts nicotinamide away from NAD+ synthesis. Inhibiting NNMT is proposed to reverse both of these effects simultaneously, while also reducing lipogenic gene expression in fat tissue.

What is the reported dose of 5-Amino-1MQ? The most commonly reported dose in research accounts is 50 mg once daily, taken orally. Some researchers report 100 mg daily, divided into two doses. No human dose-finding data is available; these ranges are derived from community reports and rodent study scaling estimates.

Is there human evidence for 5-Amino-1MQ? Human evidence is very limited. No completed human clinical trials have been published as of the knowledge cutoff. Available evidence consists primarily of rodent studies showing compelling metabolic effects. Rodent-to-human translation in metabolic research is historically unreliable. Researchers should weigh this evidence gap carefully before drawing conclusions about human efficacy.

Related Pages

Goals: Fat Loss · Metabolic Health · Longevity

Compare: NAD+ · MOTS-c · AOD-9604

Also see: Fragment 176-191 · Tirzepatide

References and Further Reading

• Neelakantan H, et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141–152.
• Kraus D, et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258–262.
• Pissios P. (2017). Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme. Trends in Endocrinology and Metabolism, 28(5), 340–353.